

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.

Since the announcement 20 December 2024, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,311,875		1,748,331,923
2 January 2025	96,000	636.79	61,132,013
3 January 2025	94,334	632.25	59,642,769
6 January 2025	95,000	623.96	59,276,145
7 January 2025	96,000	604.45	58,027,107
8 January 2025	100,000	618.34	61,833,956
9 January 2025	97,126	625.92	60,792,638
10 January 2025	99,932	633.15	63,272,401
Accumulated under the programme	2,990,267		2,172,308,952

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](https://www.novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 24,337,924 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 10 January 2025, Novo Nordisk has since 6 February 2024 repurchased a total 23,193,366 B shares at an average share price of DKK 820.76 per B share equal to a transaction value of DKK 19,036,102,830.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com